Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor
Hoffmann-La Roche
Study ID
NCT01516476
Phase
PHASE2
Status
Terminated

Conditions

  • Diabetes Mellitus Type 2

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Placebo — DRUG
    Placebo for 12 weeks
  • RO6807952 — DRUG
    multiple doses for 12 weeks
  • RO6807952 — DRUG
    multiple doses for 12 weeks
  • liraglutide — DRUG
    liraglutide for 12 weeks

Study Details

This randomized, double-blind, placebo-controlled, multi-center study will evaluate the efficacy and safety of RO6807952 in patients with diabetes mellitus type 2 inadequately controlled with metformin alone. Patients will be randomized to receive doses of RO6807952, placebo, or liraglutide. The anticipated time on study treatment is 12 weeks.

Key Dates

Start date
Nov 30, 2011
Status verified
Nov 2016
Primary completion
Jan 31, 2012
Completion
Jan 31, 2012

Study Design

Enrollment
2 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide Arm
  • Placebo Comparator: Placebo Arm
  • Experimental: RO6807952 Arm 1
  • Experimental: RO6807952 Arm 2

Primary Outcome Measure

Change in hemoglobin A1c (HA1c) [ Time Frame: Baseline and 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
-CincinnatiOhio45227-

Related Studies